Online date: May 17, 2023
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the article titled “Commentary: Topical interferon: A novel approach to uveitic macula edema” published in pages 4361-4363, Issue 12, Volume 70 of Indian Journal of Ophthalmology,[1] in the studies on topical interferon therapy in uveitic macula edema [Table 1], the prospective pilot study by Deuter et al on interferon alpha 2a for the treatment of refractory cystoid macula edema in endogenous uveitis has been published as “Topical interferon is an effective treatment option for refractory uveitic macula edema.” The corrected version is “Subcutaneous IFN alpha-2a can be a treatment option for patients with treatment resistant uveitic CME.”
Reference
1. Balamurugan S, Somanath A. Commentary:Topical interferon:A novel approach to uveitic macula edema. Indian J Ophthalmol 2022;70:4361–3.
